Comparative Pharmacology
Head-to-head clinical analysis: DESFLURANE versus KETAMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESFLURANE versus KETAMINE HYDROCHLORIDE.
DESFLURANE vs KETAMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desflurane is a volatile general anesthetic that potentiates inhibitory GABA and glycine neurotransmission and inhibits excitatory NMDA glutamate receptors, leading to neuronal hyperpolarization and reduced neuronal excitability.
Noncompetitive NMDA receptor antagonist; also interacts with opioid receptors, monoaminergic receptors, and voltage-gated calcium channels.
Induction: 3-12% inhaled, titrated to effect; maintenance: 2-6% inhaled, adjusted to maintain adequate anesthetic depth with up to 1 MAC (6.0% at 37°C, 1 atm).
Induction: 1-2 mg/kg IV, 0.5-1 mg/kg/min IV infusion for maintenance. Dissociative sedation: 1-1.5 mg/kg IV or 3-4 mg/kg IM. Pain management: 0.1-0.5 mg/kg IV bolus followed by 0.1-0.4 mg/kg/h IV infusion.
None Documented
None Documented
Clinical Note
moderateDesflurane + Torasemide
"The risk or severity of adverse effects can be increased when Desflurane is combined with Torasemide."
Clinical Note
moderateDesflurane + Etacrynic acid
"The risk or severity of adverse effects can be increased when Desflurane is combined with Etacrynic acid."
Clinical Note
moderateDesflurane + Furosemide
"The risk or severity of adverse effects can be increased when Desflurane is combined with Furosemide."
Clinical Note
moderateDesflurane + Bumetanide
Terminal elimination half-life is 3.5–4.5 minutes (context-sensitive half-life after prolonged anesthesia can be longer due to distribution, but true elimination is rapid due to low blood/gas partition coefficient).
Terminal elimination half-life of ketamine is 2.5–3 hours; norketamine half-life is approximately 4 hours. Context: Prolonged elimination may occur with hepatic impairment or high-dose infusions.
Primarily eliminated via exhalation; minimal hepatic metabolism (<0.02%). Renal excretion of metabolites negligible. >99% excreted unchanged by lungs.
Ketamine is primarily metabolized in the liver via N-demethylation to norketamine. Renal excretion accounts for approximately 90% of the dose, with 4% as unchanged drug, 16% as norketamine, and the remainder as conjugated metabolites. Fecal excretion is minimal (<5%).
Category C
Category C
General Anesthetic
General Anesthetic
"The risk or severity of adverse effects can be increased when Desflurane is combined with Bumetanide."